The undruggable is now drugged: Daraxonrasib and the end of RAS nihilism in pancreatic cancer

PathGen Diagnostik Teknologi · 2026-10-28

Daraxonrasib doubled median overall survival (13.2 vs. 6.6 months) and progression-free survival (7.3 vs. 3.5 months) compared to chemotherapy in previously treated metastatic pancreatic cancer. It also significantly delayed pain deterioration, preserved quality of life longer, and proved much better tolerated, validating a breakthrough RAS(ON) targeting strategy for historically "undruggable" pancreatic tumors.

Pancreatic Cancer has long been one of oncology’s most humbling challenges. More than 90% of cases are driven by oncogenic RAS mutations, yet for four decades, RAS was considered “undruggable”. Patients who progressed after first-line therapy had few options: cytotoxic chemotherapy offered a response rate below 15%, median progression-free survival of just 3-4 months, and a median overall survival of only 6-7 months.

Recent research conducted by Eileen M. O’Reilly et.al found that daraxonrasib, an oral RAS(ON) multiselective tri-complex inhibitor that binds cyclophilin A to engage and suppress the active GTP-bound state of RAS marks a genuinely new mechanistic chapter. This is not an incremental tweak to existing chemotherapy. It is a targeted attack on the mutation that drives the disease in the first place.

The RASolute 302 trial enrolled 500 patients across 59 sites in six countries. All had previously treated metastatic PDAC; 91.8% carried RAS G12 mutations. Patients were randomized 1:1 to daraxonrasib (300 mg oral once daily) or investigator’s choice of chemotherapy.

The finding showed that median overall survival doubled at 13.2 months with daraxonrasib versus 6.6 months with chemotherapy. Median progression-free survival more than doubled at 7.3 months versus 3.5 months. The objective response rate was nearly three times higher. Both primary endpoints were highly statistically significant (P<0.001).

Perhaps the most striking context: the 13.2-month median overall survival observed in this second-line trial is comparable to or exceeds what landmark first-line regimens like FOLFIRINOX and gemcitabine/nab-paclitaxel have historically achieved (8.5-11.1 months). That comparison warrants caution given differences in patient populations, but it reflects just how dramatic the shift is.

Efficacy alone does not tell the full story. Pain is one of the most debilitating and feared symptoms of pancreatic cancer. In this trial, the median time to pain deterioration was 9.0 months with daraxonrasib versus only 3.7 months with chemotherapy. Global health status quality of life was preserved for significantly longer as well (5.6 vs 2.4 months median to deterioration).

Patients in the daraxonrasib group didn’t just live longer. They reported better quality of life, more days without pain, and stayed on treatment for a median of 6.2 months, compared to 1.5-3.2 months across chemotherapy regimens. Grade 3+ adverse events occurred in 61.8% vs 69.6%, and treatment discontinuation due to adverse events was just 1.2% vs 11.2%.

Why This Matters Beyond The Numbers

This trial carries implications that extend well beyond second-line pancreatic cancer. It is a proof of concept that sustained inhibition of active RAS, the RAS(ON) state can produce meaningful clinical benefit in a disease where the RAS-MAPK pathway is the dominant driver. If the same logic holds upstream, in first-line settings, or in combination strategies, the potential is enormous.

It also demonstrates that biotech-driven mechanistic innovation, not just optimization of existing cytotoxic regimens, is where the next wave of progress in pancreatic cancer will come from. Revolution Medicines built this program from a fundamental scientific insight about RAS biology and the clinical results appear to bear that out.

For patients with previously treated metastatic pancreatic cancer, a population with historically dismal outcomes, daraxonrasib offers what may be the most meaningful survival benefit ever demonstrated in a randomized controlled trial in this setting. For the field, it validates a new therapeutic paradigm. For researchers and clinicians, it raises an urgent and exciting question:

How far can RAS(ON) inhibition go?

Read the LinkedIn issue